Abstract
Fifty-seven patients with severe Graves’ ophthalmopathy were treated with corticosteroids. Therapeutic outcome was assessed according to predetermined criteria as response (n = 37) or non-response (n = 20) to therapy. Patients were typed for HLA-A, -B, -C, -DR and -DQ. HLA-DR4 was completely absent in the 20 non-responder patients (corrected p value = 0.042). In the responder group 14 of the 37 patients were HLA-DR4 positive. This study shows that in Graves’ ophthalmopathy patients the presence of HLA-DR4 is associated with a good response to corticosteroid therapy. The frequency of HLA-DR4 in the Graves’ ophthalmopathy population as a whole, however, was not different from normal (25% versus 26%). But as reported previously, the frequency of HLA-DR3 was significantly increased in the Graves’ ophthalmopathy patients when compared to healthy blood donors (47% versus 24%, corrected p value = 0.02). No significant deviations were found in the HLA-A, -B, or -C loci.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wiersinga W.M., Smit T., Van der Gaag R., Koornneef L. Temporal relationship between onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease. J. Endocrinol. Invest. 11: 615, 1988.
Kendall-Taylor P. The pathogenesis of Graves’ ophthalmopathy. Clin. Endocrinol. Metab. 14: 331, 1985.
Wiersinga W.M., Smit T., Schuster-Uittenhoeve A.L.J., Van der Gaag R., Koornneef L. Therapeutic outcome of prednisone medication and of orbital irradiation in patients with Graves’ ophthalmopathy. Ophthalmologica 197: 75, 1988.
Allannic H., Fauchet R., Lorcy Y., Heim J., Gueguen M., Leguerrier A.M., Genetet B. HLA and Graves’ disease: an association with HLA-DRw3. J. Clin. Endocrinol. Metab. 51: 863, 1980.
Farid N.R., Bear J.C. The human major histocompatibility complex and endocrine disease. Endocr. Rev. 2: 50, 1981.
Frecker M., Stenszky V., Balazs C., Kozma L., Kraszits E., Farid N.R. Genetic factors in Graves’ ophthalmopathy. Clin. Endocrinol. (Oxf.) 25: 479, 1986.
Weetman A.P., So A.K., Warner C.A., Foroni L., Fells P., Shine B. Immunogenetics of Graves’ ophthalmopathy. Clin. Endocrinol. (Oxf.) 28: 619, 1988.
Mayr W.R., Ludwig H. Schernthaner G., Hofer R. HLA-CW3 in thyrotoxicosis patients with and without endocrine ophthalmopathy. Tissue Antigens 7: 243, 1976.
Bech K., Lumholtz B., Nerup J., Thomsen M., Platz P., Ryder L.P., Svejgaard A., Siersbaek-Nielsen K., Hansen J.M., Larsen J.H. HLA antigens in Graves’ disease. Acta Endocrinol. (Copenh.) 86: 510, 1977.
McGregor A.M., Smith B.R., Hall R., Peterson M.M., Miller M., Dewar P.J. Prediction of relapse in hyperthyroid Graves’ disease. Lancet 2: 1101, 1980.
Schleusener H., Schwander J., Holl G., Badenhoop K., Hensen J., Finke R., Schernthaner G., Mayr W.R., Kotulla P. Do HLA-DR typing and measurement of TSH-re-ceptor antibodies help in the prediction of the clinical course of Graves’ thyrotoxicosis after antithyroid drug treatment? Acta Endocrinol. (Copenh.) (Suppl.) 281: 318, 1987.
De Bruin T.W.A., Bolk J.H., Bussemaker J.K., Stijner T., Schreuder G.M.T., De Vries R.R.P., Van der Heide D. Graves’ disease: immunological and immunogenetic indicators of relapse. Br. Med. J. 296:1292, 1988.
Prummel M.F., Mourits M.P., Berghout A., Krenning E.P., Van der Gaag R., Koornneef L., Wiersinga W.M. Prednisone versus Cyclosporine in the treatment of Graves’ ophthalmopathy. A randomized clinical trial. N. Engl. J. Med. 321: 1353, 1989.
Werner S.C. Modification of the classification of the eye changes of Graves’ disease: recommendations of the ad hoc committee of the American Thyroid Association. J. Clin. Endocrinol. Metab. 44: 203, 1977.
Donaldson S.S., Bagshaw M.A., Kriss J.P. Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab. 37: 276, 1973.
Mittal K.D., Mickey M.R., Singal D.P., Terasaki P.I. Serotyping for homotransplantation. XVIII. Refinement of microdroplet lymphocyte toxicity test. Transplantation 6: 913, 1968.
Van Rood J.J., Van Leeuwen A., Ploem J.S. Simultaneous detection of two cell populations by two-colour fluorescence and application to the recognition of β-cell determinants. Nature 262: 795, 1976.
Wiersinga W.M., Smit T., Van der Gaag R., Mourits M.P., Koornneef L. Clinical presentation of Graves’ ophthalmopathy. Ophthalmic Res. 21: 73, 1989.
Frecker M., Mercer G., Skanes V.M., Farid N.R. Major histocompatibility complex (MHC) factors predisposing to and protecting against Graves’ eye disease. Autoimmunity 7: 307, 1988.
Van der Gaag R., Broersma L., Mourits M.P., Koornneef L. Wiersinga W.M., Prummel M.F., Berghout A. Circulating monocyte migration inhibitory factor in serum of Graves’ ophthalmopathy patients: a pa rameter for disease activity? Clin. Exp. Immunol. 75: 275, 1989.
Mourits M.P., Koornneef L., Wiersinga W.M., Prummel M.F, Berghout A. Van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br. J. Ophthalmol. 73: 639, 1989.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van der Gaag, R., Wiersinga, W.M., Koornneef, L. et al. HLA-DR4 associated response to corticosteroids in Graves’ ophthalmopathy patients. J Endocrinol Invest 13, 489–492 (1990). https://doi.org/10.1007/BF03348605
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348605